Scancell Holdings plc (LON:SCLP – Get Free Report)’s share price reached a new 52-week high on Monday . The stock traded as high as GBX 13.25 and last traded at GBX 13, with a volume of 3623221 shares traded. The stock had previously closed at GBX 11.81.
Scancell Stock Up 10.1%
The company has a debt-to-equity ratio of -566.79, a current ratio of 3.42 and a quick ratio of 13.01. The stock has a 50 day simple moving average of GBX 10.17 and a 200-day simple moving average of GBX 10.01. The firm has a market cap of £134.91 million, a PE ratio of -10.32 and a beta of 0.35.
About Scancell
Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.
Further Reading
- Five stocks we like better than Scancell
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
